Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | FPR3 | P25089 | 2/20 | 0.46 |
| ▸ | FPR2 | P25090 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11824629 | 0.98 | CYP1A2 (0.64) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 | |
| SCHEMBL805269 | 0.98 | CYP1A2 (0.63) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 | |
| Hydrochloric Acid SCHEMBL15169053 | 0.96 | CYP1A2 (0.61) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 | |
| SCHEMBL12522442 | 0.94 | PAOX (0.69) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 | |
| Hydrochloric Acid SCHEMBL5205856 | 0.91 | PAOX (0.60) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 | |
| Hydrochloric Acid SCHEMBL15168995 | 0.89 | PAOX (0.69) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 | |
| SCHEMBL1286683 | 0.86 | ALDH1A1 (0.64) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 | |
| SCHEMBL13993956 | 0.86 | ALDH1A1 (0.64) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 | |
| SCHEMBL23373543 | 0.86 | PAOX (0.59) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 | |
| Hydrochloric Acid SCHEMBL29360031 | 0.84 | ALDH1A1 (0.61) | CYP1A2MAPK1SMN1; SMN2PAOXALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-10844459-B2 | Process for extracting and recovering tantalum present in an acid aqueous phase by means of an ionic liquid, and use of such an ionic liquid for extracting the tantalum from an acid aqueous phase | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-11-24 | — | — | US | disclosed |
| US-10844459-B2 | Process for extracting and recovering tantalum present in an acid aqueous phase by means of an ionic liquid, and use of such an ionic liquid for extracting the tantalum from an acid aqueous phase | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-11-24 | — | — | US | disclosed |
| EP-3334846-B1 | PROCESSES FOR EXTRACTING AND RECOVERING TANTALUM PRESENT IN AN ACID AQUEOUS PHASE BY MEANS OF AN IONIC LIQUID, AND USE OF SUCH AN IONIC LIQUID FOR EXTRACTING THE TANTALUM FROM AN ACID AQUEOUS PHASE | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| EP-3334846-B1 | PROCESSES FOR EXTRACTING AND RECOVERING TANTALUM PRESENT IN AN ACID AQUEOUS PHASE BY MEANS OF AN IONIC LIQUID, AND USE OF SUCH AN IONIC LIQUID FOR EXTRACTING THE TANTALUM FROM AN ACID AQUEOUS PHASE | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| EP-3334846-A1 | PROCESSES FOR EXTRACTING AND RECOVERING TANTALUM PRESENT IN AN ACID AQUEOUS PHASE BY MEANS OF AN IONIC LIQUID, AND USE OF SUCH AN IONIC LIQUID FOR EXTRACTING THE TANTALUM FROM AN ACID AQUEOUS PHASE | Centre National De La Recherche Scientifique (FR) | 2018-06-20 | — | — | EP | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-7569588-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569588-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090176767-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176767-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20080312224-A1 | Oxaphenanthrene Derivatives | MERCK PATENT GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-7288552-B2 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | STC NARA CO., LTD. (KR) | 2007-10-30 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP1A2 2103/4885MAPK1 549/4885SMN1; SMN2 1984/4885 |
| US-20080312224-A1 | Oxaphenanthrene Derivatives | CYP3A43, CYP1A1, CYP1A2 | CYP1A2 3/4885MAPK1 3176/4885SMN1; SMN2 4610/4885 |
| US-20090176767-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CYP1A2 333/4885MAPK1 3316/4885SMN1; SMN2 4181/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | CYP1A2 4232/4885MAPK1 2101/4885SMN1; SMN2 985/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | CYP1A2 783/4885MAPK1 3526/4885SMN1; SMN2 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.